Filing Details

Accession Number:
0000899243-22-025233
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-07-06 07:30:18
Reporting Period:
2022-06-03
Accepted Time:
2022-07-06 07:30:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1754068 Allovir Inc. ALVR () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1743662 B Jeroen Beek Van C/O Allovir, Inc.
1100 Winter Street
Waltham MA 02451
Chief Commercial Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-06-03 515 $3.63 389,011 No 4 S Direct
Common Stock Acquisiton 2022-07-01 14,000 $0.00 403,011 No 4 A Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 A Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Acquisiton 2022-07-01 26,000 $0.00 26,000 $4.13
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
26,000 2032-07-01 No 4 A Direct
Footnotes
  1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units ("RSUs"), and does not represent a discretionary trade by the Reporting Person.
  2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.60 to $3.67. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
  3. The shares reported in this transaction represent RSUs issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.
  4. 25% of this option shall vest and become exercisable on July 1, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.